Heron Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Adam Morgan

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Morgan”): 88,295,437 for, 3,381,282 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,026,037 for, 238,090 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Christian Waage

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Waage”): 85,276,872 for, 6,399,195 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 8,380,271 for, 1,883,855 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Collard

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Collard”): 87,289,779 for, 4,336,869 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,141 for, 216,984 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Johnson

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Johnson”): 87,703,801 for, 3,972,919 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,029,402 for, 234,724 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Michael Kaseta

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Kaseta”): 88,236,408 for, 3,424,597 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,148 for, 216,978 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Sharmila Dissanaike, M.D., FACS, FCCM

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Dissanaike”): 87,960,023 for, 3,729,614 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,232,767 for, 31,360 against.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Tom Cusack

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Cusack”): 88,537,725 for, 3,088,305 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,148 for, 216,978 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF CONVERTIBLE SENIOR UNSECURED PROMISSORY NOTES DUE 2031 HELD BY SEVERAL NON-AFFILIATED PURCHASERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING PRIOR TO SUCH ISSUANCE.

Heron Therapeutics, Inc.’s own tally for this item (“1. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at the option of the holder, of convertible senior unsecured promissory note”): 89,632,206 for, 5,575,457 against — passed, per its Form 8-K filed October 15, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The votes with respect to each of the two proposals voted on at the Special Meeting are set forth below: Proposal 1: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at t…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 11,738,277 for, 134,717 against.

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Description as filed by funds: TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF THE COMPANY'S SERIES A CONVERTIBLE PREFERRED STOCK HELD BY SEVERAL NON-AFFILIATED HOLDERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING PRIOR TO SUCH ISSUANCE.

Heron Therapeutics, Inc.’s own tally for this item (“2. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by sever”): 91,534,602 for, 3,672,091 against — passed, per its Form 8-K filed October 15, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which …”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 11,872,994 for.

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Description as filed by funds: TO AMEND THE COMPANY'S 1997 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 10,000,000 SHARES.

Heron Therapeutics, Inc.’s own tally for this item (“5. The amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares”): 83,765,950 for, 6,496,205 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5: The Company's stockholders approved the amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,117 for, 217,000 against, 10 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2007 AMENDED AND RESTATED EQUITY INCENTIVE PLAN, TO, AMONG OTHER THINGS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 16,560,000 SHARES.

Heron Therapeutics, Inc.’s own tally for this item (“4. The amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional”): 75,620,741 for, 13,846,030 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: The Company's stockholders approved the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares:”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 9,029,248 for, 1,234,863 against, 16 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: TO RATIFY, ON A NONBINDING ADVISORY BASIS, THE ADOPTION OF THE TAX BENEFITS PRESERVATION PLAN.

Heron Therapeutics, Inc.’s own tally for this item (“6. On a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan”): 88,182,895 for, 3,442,815 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 6: The Company's stockholders ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 9,900,066 for, 364,060 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCAL YEAR ENDED DECEMBER 31, 2025.

Heron Therapeutics, Inc.’s own tally for this item (“3. On a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025”): 77,315,474 for, 12,117,861 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 36 managers: 9,557,334 for, 706,779 against, 16 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 111 managers: 60,606,754 for, 7,588,482 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Heron Therapeutics, Inc.’s own tally for this item (“2. The appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 139,715,514 for, 1,706,193 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders ratified the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,258,627 for, 5,500 against, 1 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.